SG11201605916QA - Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine - Google Patents
Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amineInfo
- Publication number
- SG11201605916QA SG11201605916QA SG11201605916QA SG11201605916QA SG11201605916QA SG 11201605916Q A SG11201605916Q A SG 11201605916QA SG 11201605916Q A SG11201605916Q A SG 11201605916QA SG 11201605916Q A SG11201605916Q A SG 11201605916QA SG 11201605916Q A SG11201605916Q A SG 11201605916QA
- Authority
- SG
- Singapore
- Prior art keywords
- methyl
- aminooxetan
- benzothiazepin
- quinazolin
- dioxo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/071331 | 2014-01-24 | ||
| PCT/EP2015/051066 WO2015110446A1 (en) | 2014-01-24 | 2015-01-21 | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201605916QA true SG11201605916QA (en) | 2016-08-30 |
Family
ID=52358790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201605916QA SG11201605916QA (en) | 2014-01-24 | 2015-01-21 | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10005770B2 (en) |
| EP (2) | EP3248969B1 (en) |
| JP (1) | JP6397501B2 (en) |
| KR (1) | KR101841866B1 (en) |
| CN (2) | CN109879837B (en) |
| AR (2) | AR099134A1 (en) |
| AU (1) | AU2015208244B2 (en) |
| BR (1) | BR112016016978B1 (en) |
| CA (1) | CA2934225C (en) |
| ES (2) | ES2788900T3 (en) |
| HR (2) | HRP20200680T1 (en) |
| IL (1) | IL245882B (en) |
| MX (1) | MX368110B (en) |
| MY (1) | MY176210A (en) |
| NZ (1) | NZ721534A (en) |
| PL (2) | PL3097098T3 (en) |
| RU (1) | RU2664643C2 (en) |
| SG (1) | SG11201605916QA (en) |
| SI (2) | SI3248969T1 (en) |
| WO (1) | WO2015110446A1 (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016184832A1 (en) | 2015-05-20 | 2016-11-24 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| CN108290882B (en) * | 2015-07-16 | 2021-07-06 | 豪夫迈·罗氏有限公司 | Crystalline forms of a 4-quinazolinamine derivative for the treatment of respiratory syncytial virus infection |
| PL3324977T3 (en) | 2015-07-22 | 2022-11-14 | Enanta Pharmaceuticals, Inc. | Benzodiazepine derivatives as rsv inhibitors |
| MX2018005890A (en) | 2015-11-12 | 2018-08-15 | Hoffmann La Roche | Compositions for treating spinal muscular atrophy. |
| ES2879995T3 (en) | 2015-12-10 | 2021-11-23 | Ptc Therapeutics Inc | Methods for treating Huntington's disease |
| CN108137579B (en) | 2015-12-10 | 2022-01-07 | 豪夫迈·罗氏有限公司 | Bridged piperidine derivatives |
| CN108017599B (en) * | 2016-11-04 | 2020-03-03 | 上海爱科百发生物医药技术有限公司 | Synthesis method of [3- (aminomethyl) -oxetane-3-yl ] carbamic acid p-methoxybenzyl ester p-chlorobenzoate |
| EA201992878A1 (en) | 2017-06-05 | 2020-05-08 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | COMPOUNDS FOR TREATMENT OF HUNTINGTON'S DISEASE |
| BR112019027717A2 (en) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics, Inc. | methods to treat huntington's disease |
| MX2019015580A (en) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Methods for treating huntington's disease. |
| WO2019006295A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as rsv inhibitors |
| CN112135815A (en) | 2018-03-27 | 2020-12-25 | Ptc医疗公司 | Compounds for the treatment of huntington's disease |
| EP3814360A1 (en) | 2018-06-27 | 2021-05-05 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| AU2019294478B2 (en) | 2018-06-27 | 2023-03-23 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating Huntington's disease |
| US11254664B2 (en) | 2019-03-18 | 2022-02-22 | Enanta Pharmaceuticals, Inc. | Benzodiazepine derivatives as RSV inhibitors |
| KR20220101083A (en) | 2019-10-04 | 2022-07-19 | 이난타 파마슈티칼스, 인코포레이티드 | Antiviral Heterocyclic Compounds |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| WO2021083290A1 (en) * | 2019-10-31 | 2021-05-06 | Shanghai Ark Biopharmaceutical Co. Ltd. | Respiratory syncytial virus fusion protein inhibitor compositions and methods for the treatment and prophylaxis of rsv diseases using the same |
| CN113149977A (en) * | 2020-01-22 | 2021-07-23 | 苏州爱科百发生物医药技术有限公司 | Synthesis and application of respiratory syncytial virus inhibitor |
| UY39032A (en) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | HETEROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS |
| CN111518055A (en) * | 2020-05-16 | 2020-08-11 | 西安都创医药科技有限公司 | Preparation method of benzothiazepine oxide, product prepared by preparation method and application of product |
| CN111548325A (en) * | 2020-05-16 | 2020-08-18 | 西安都创医药科技有限公司 | Preparation method of halogenated benzothiazepine compound, product prepared by preparation method and application of product |
| CN111620838A (en) * | 2020-05-16 | 2020-09-04 | 西安都创医药科技有限公司 | Preparation method of chloro-benzothiepin compound, product prepared by preparation method and application of chloro-benzothiepin compound |
| CN111574475B (en) * | 2020-06-03 | 2022-09-20 | 西安都创医药科技有限公司 | Preparation method of halogenated benzothiepin oxide, product prepared by preparation method and application of product |
| US11534439B2 (en) | 2020-07-07 | 2022-12-27 | Enanta Pharmaceuticals, Inc. | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors |
| US11945824B2 (en) | 2020-10-19 | 2024-04-02 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| EP4298103A1 (en) | 2021-02-26 | 2024-01-03 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1383409A (en) * | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
| SE9901573D0 (en) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
| CA2516329A1 (en) * | 2003-02-21 | 2004-09-02 | Pharmacia & Upjohn Company Llc | Exo-(t-butyl 2r(+))-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate, intermediates, and process to prepare and isolate them |
| ATE372324T1 (en) * | 2003-04-30 | 2007-09-15 | Inst For Pharm Discovery Inc | SUBSTITUTED HETEROARYL COMPOUNDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES |
| DE102004045648A1 (en) * | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New betamimetics for the treatment of respiratory diseases |
| JP4899385B2 (en) * | 2005-09-06 | 2012-03-21 | 宇部興産株式会社 | Method for producing 3-aminomethyloxetane compound |
| TW201215387A (en) * | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| US9040545B2 (en) | 2010-08-20 | 2015-05-26 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors |
| US8871756B2 (en) * | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
| MX342153B (en) | 2011-10-11 | 2016-09-15 | Hoffmann La Roche | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease. |
| CN105392787B (en) * | 2013-05-14 | 2017-11-24 | 豪夫迈·罗氏有限公司 | For treating and preventing the azepine oxindole of respiratory syncytial virus infection |
| JP2016518421A (en) * | 2013-05-14 | 2016-06-23 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Aza-oxo-indoles for the treatment and prevention of respiratory syncytial virus infection |
-
2015
- 2015-01-20 AR ARP150100146A patent/AR099134A1/en active IP Right Grant
- 2015-01-21 ES ES15700600T patent/ES2788900T3/en active Active
- 2015-01-21 CN CN201910222238.1A patent/CN109879837B/en active Active
- 2015-01-21 PL PL15700600T patent/PL3097098T3/en unknown
- 2015-01-21 ES ES17176794T patent/ES2789798T3/en active Active
- 2015-01-21 RU RU2016133187A patent/RU2664643C2/en active
- 2015-01-21 CA CA2934225A patent/CA2934225C/en active Active
- 2015-01-21 SI SI201531184T patent/SI3248969T1/en unknown
- 2015-01-21 EP EP17176794.0A patent/EP3248969B1/en active Active
- 2015-01-21 BR BR112016016978-6A patent/BR112016016978B1/en active IP Right Grant
- 2015-01-21 MX MX2016009514A patent/MX368110B/en active IP Right Grant
- 2015-01-21 CN CN201580005504.5A patent/CN106414436B/en active Active
- 2015-01-21 PL PL17176794T patent/PL3248969T3/en unknown
- 2015-01-21 SG SG11201605916QA patent/SG11201605916QA/en unknown
- 2015-01-21 SI SI201531193T patent/SI3097098T1/en unknown
- 2015-01-21 KR KR1020167020106A patent/KR101841866B1/en active IP Right Grant
- 2015-01-21 MY MYPI2016702654A patent/MY176210A/en unknown
- 2015-01-21 NZ NZ721534A patent/NZ721534A/en unknown
- 2015-01-21 WO PCT/EP2015/051066 patent/WO2015110446A1/en active Application Filing
- 2015-01-21 AU AU2015208244A patent/AU2015208244B2/en active Active
- 2015-01-21 EP EP15700600.8A patent/EP3097098B1/en active Active
- 2015-01-21 JP JP2016548177A patent/JP6397501B2/en active Active
-
2016
- 2016-05-26 IL IL245882A patent/IL245882B/en active IP Right Grant
- 2016-07-21 US US15/216,501 patent/US10005770B2/en active Active
-
2018
- 2018-05-24 US US15/988,570 patent/US10253022B2/en active Active
-
2020
- 2020-03-16 AR ARP200100726A patent/AR118371A2/en unknown
- 2020-04-28 HR HRP20200680TT patent/HRP20200680T1/en unknown
- 2020-05-04 HR HRP20200715TT patent/HRP20200715T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL245882B (en) | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine | |
| SI3433285T1 (en) | An improved process for the preparation of sugammadex | |
| IL247833A0 (en) | 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation | |
| ZA201606386B (en) | 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation | |
| ZA201706795B (en) | Process for the preparation of dicycloplatin | |
| HK1258964A1 (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
| HUE036789T2 (en) | Synthetic method for the preparation of 1,2-Benzisothiazolin-3-one | |
| ZA201608442B (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
| SG11202005889WA (en) | Process for the preparation of methyl mercaptan | |
| EP3207041A4 (en) | An improved process for the preparation of lurasidone hydrochloride | |
| IL275480A (en) | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds | |
| ZA202004349B (en) | Fluoralkenyl compounds, process for preparation and use thereof | |
| IL268835B (en) | Process for the preparation of 2-cyanoimidazole compounds | |
| IL247895A0 (en) | Process for the preparation of n-[3-(benzylcarbamoyl)phenyl]-1 h-pyrazole-5-carboxamides | |
| GB2561089B (en) | Process for the preparation of 17beta-hydroxy-des-a-androst-9, 10-en-5-one | |
| ZA202002116B (en) | Process for the preparation of piperine | |
| HK1245267A1 (en) | Asymmetric process for the preparation of thieno-indoles derivatives | |
| ZA201603729B (en) | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine | |
| IL251229B (en) | Process for the preparation of 5-bromo-1,2,3-trichlorobenzene | |
| IL274560A (en) | Process for the preparation of raltegravir | |
| IL247751B (en) | Method for the preparation of n-[(6-chloropyridino-3-yl)methyl]-2,2-difluoroethane-1-amine by the alkylation of 2,2-difluoroethylamine | |
| GB201603886D0 (en) | Compounds for the treatment of type 2 diabetes | |
| GB201603882D0 (en) | Compounds for the treatment of type 2 diabetes | |
| HUP1500451A2 (en) | Processes for the preparation of 1,4,7-triaza-cyclononane derivatives and intermediates |